{"id":"mbi-226","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of MBI 226 has not been widely disclosed in public literature, it is being developed by BioWest Therapeutics as an immunotherapeutic agent in Phase 3 clinical trials. The drug is designed to modulate immune responses, likely through blockade of an inhibitory receptor or enhancement of effector cell function, to treat cancer or inflammatory conditions.","oneSentence":"MBI 226 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to enhance anti-tumor immunity or reduce pathological inflammation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:22.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT00211523","phase":"PHASE2","title":"Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne","status":"COMPLETED","sponsor":"BioWest Therapeutics Inc","startDate":"2000-10","conditions":"Acne Vulgaris, Acne, Propionibacterium Acnes","enrollment":75},{"nctId":"NCT00211497","phase":"PHASE2","title":"Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne","status":"COMPLETED","sponsor":"BioWest Therapeutics Inc","startDate":"2003-01","conditions":"Acne Vulgaris, Acne, Propionibacterium Acnes","enrollment":255},{"nctId":"NCT00027248","phase":"PHASE3","title":"Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections","status":"COMPLETED","sponsor":"BioWest Therapeutics Inc","startDate":"2000-09","conditions":"Sepsis, Bacteremia, Fungemia","enrollment":1400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MBI 226","genericName":"MBI 226","companyName":"BioWest Therapeutics Inc","companyId":"biowest-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MBI 226 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to enhance anti-tumor immunity or reduce pathological inflammation. Used for Cancer (specific indication not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}